CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
January 26, 2024 07:30 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant dosesAll assessable nectin-4 positive study participants with mUC and cervical cancer treated...
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
January 23, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today that the abstract for the first-in-human Phase 1...
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
January 09, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
CRB-601 is designed to block the activation of latent TGFβ in the tumor microenvironmentPhase 1 clinical study set to commence H1 2024Pre-clinical data presented demonstrates robust anti-tumor...
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
December 18, 2023 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Data from dose escalation study for CRB-701, a Nectin-4 ADC to treat solid tumors, on track for release in early 2024 along with start of U.S./EU StudyIND Submission for CRB-601, an αvβ8 Monoclonal...
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
November 02, 2023 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that results from...
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
October 17, 2023 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
CRB-913 is a novel highly peripherally restricted CB1 inverse agonist with potent monotherapy efficacy in DIO mouse modelWeight loss and related outcomes markedly enhanced in combination with...
Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
October 16, 2023 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on...
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
October 03, 2023 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a...
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
August 12, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinicAugmenting the pipeline through...